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Chapter 1 
 
Single nucleotide polymorphisms and 
protein variants 
 
Polymorphisms are generally defined as variations in DNA 
sequence that occur in at least 1% of the population. The vast majority of 
variants are single nucleotide polymorphisms, or SNPs. Because the 
human genome contains 3 billion nucleotides, and variations between 
individuals occur approximately once in each 300 base pair, 
approximately 10 million SNPs are expected to exist between any 2 
genomes. Because only a fraction of these SNPs is likely to prove 
relevant to drug response, the ultimate goal will be to identify all 
functionally important variants. 
Major pharmaceutical companies have responded to the growing 
emphasis on individualized therapy to improve drug efficacy and safety 
with large investments in pharmacogenomics research. The availability 
of SNP maps at high-resolution and DNA microarray, enables the basic 
research and the studies a clinical trials level to better identify disease-
susceptibility genes for prognosis, drug discovery, and selection of 
therapy. If risk for a given disease is predicted to be high, as judged by 
the SNP pattern of a patient, preventive therapy and lifestyle 
adjustments (diet, exercise, etc.) may also be implemented. 
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A comprehensive SNP map will contain genetic variants relevant to 
drug transport, metabolism, and receptor interaction and, therefore, it needs to 
be considered in drug selection. Moreover, a comprehensive SNP map may 
also serve to alert the therapist when careful drug dosage monitoring is 
required. Stratifying patient populations using genome-wide SNP maps 
presents a major challenge to the pharmaceutical industry. The outcome from 
applying such an approach cannot be accurately gauged at present. Genetic 
heterogeneity appears to be a significant source of variability observed in the 
response to drugs. This variability means that information pertaining to 
interethnic and interindividual genetic differences can facilitate rational drug 
discovery in order to avoid or minimize the incidence of adverse events in 
clinical trials. 
The success of this approach depends in large part on assembling an 
extensive, high-quality database of informative SNPs. Ultimately the vision 
of pharmacogenomics encompasses a genetic profile for each individual, 
containing sufficient information to select which drugs are most likely to be 
safe and effective in that person. The same insight will be of great importance 
in preventive health care, arguably the most desirable goal.  
The dynamic complexity of the human genome, multigenic disease 
origins, and involvement of numerous genes in drug response impede the 
effective application of genome-wide SNP scanning in the clinic. Drug 
responses will most likely be associated with patterns of multiple 
polymorphically expressed traits, rather than single causative 
polymorphisms. Such patterns of genetic variants differ among distinct ethnic 
groups. This factor could obscure prediction of disease susceptibility and 
drug response across patient populations, and it points out to the need to 
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genetically stratify patients for clinical pharmacogenomic studies (Mancinelli 
et al., 2000). 
SNPs may fall within coding as much as non-coding, or in the 
intergenic regions. SNPs within a coding sequence do not necessarily change 
the amino acid sequence of the protein that is translated from it, due to 
degeneracy of the genetic code. SNPs in the coding region are of two types, 
synonymous and nonsynonymous SNPs. Synonymous SNPs do not affect the 
protein sequence while nonsynonymous SNPs change the amino acid 
sequence of protein. The nonsynonymous SNPs are of two types: missense 
and nonsense. A missense mutation is a point mutation in which a single 
nucleotide change the resulting amino acid, while on the other hand the 
nonsense mutation corresponds to a premature stop codon leading to 
truncation of the resulting protein (Esch e al., 2015). 
SNPs that are not in protein-coding regions may still affect gene 
splicing, transcription factor binding, messenger RNA degradation, or the 
sequence of non-coding RNA. SNPs located within the coding or regulatory 
regions of genes can cause qualitative and quantitative changes in gene 
expression, RNA splicing, protein translation, or gene function. As reported 
by The International Human Genome Sequencing Consortium 2001, only 
about 5% of the human genome codes for the production of proteins and 
most SNPs are found outside coding sequences. These variations may have 
effects in gene expression and regulation, by interrupting regulatory regions 
and affecting transcription factor binding. Millions of human SNPs have been 
identified so far, and these variants could be strongly correlated with 
phenotypic variations of traits/diseases (Cao et al, 2017). Genetic variation 
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can cause changes in phenotype if expression levels are altered or pre-mRNA 
splicing is affected. 
Coding SNPs, especially nonsynonymous coding SNPs (nsSNPs, also 
referred to as missense mutations) are of particular interest, because the 
single amino acid substitution may affect the structure and/or function of the 
protein itself (Zhou et al, 2010), as reports in many studies (Chasman and 
Adams, 2001; Ng and Henikoff, 2002; Ramensky et al, 2002). 
Structural studies have been implemented during the last decades 
since amino acid residue change has been found important for the protein 3-D 
structure (Altshuler et al, 2008; Botstein et al, 2003). Sequence changes at the 
amino acid level influence the shape, function, or binding properties of a 
given protein (Bhattacharya et al, 2017). 
Non-synonymous SNPs (nsSNPs) cause changes in the amino acid 
residues and are important factors contributing to the functional diversity of 
the encoded proteins (Yates et al, 2003; Wang and Moult, 2001; Wang and 
Moult, 2003). Non-synonymous SNPs may also affect gene regulation for 
example by altering DNA and transcriptional binding factors and maintaining 
the structural integrity of cells and tissues. In addition, nsSNPs affect the 
functional roles of proteins involved in signal transduction of visual, 
hormonal, and other stimuli (Rajasekaran et al, 2007; Gfeller et al, 2014). 
Point mutation of a particular residue can have different effect on 
protein structure and function (from no effect to complete disruption of its 
function). Amino acids with similar size and physico-chemical properties 
may have mild effect (e.g. substitution from leucine to valine). While 
changes in crucial area of protein can change the overall arrangement of 
5 
protein contacts. Important for example are the secondary structure elements 
destruction usually driven by substitution of proline residues. Many 
algorithms have been developed to predict the effect of amino acid changes 
in a protein structure. The consequences of missense mutations may be 
difficult to predict because of their diverseness and because a single amino 
acid change may lead to multiple effects.  
Human diseases can be classified as monogenic or multifactorial 
(Janssens et al 2008). Monogenic diseases are caused by alterations in a 
single gene, and they segregate in families according to the traditional 
Mendelian principles of inheritance (Martorana et al, 2017). But, the vast 
majority of human diseases can be classified as multifactorial (Manolio et al, 
2009). These conditions are also referred to as complex diseases, and they are 
responsible for most of the burden on our health care system (McCarthy, M. 
I., & MacArthur, D. G.,2017). Examples of these conditions include 
cardiovascular disease, cancer, type-2 diabetes, and a number of birth defects 
and psychiatric disorders (Avior et al, 2016). Notably about 40 SNPs have 
been shown to link with type-2 diabetes (McCarthy, M. I. 2010). By 
definition, complex diseases are caused by variation in many genes, and they 
may or may not be influenced by environment. The prediction of the 
pathogenicity of a nsSNP is based on the degree to which the function of the 
protein is impaired by the amino acid substitution; but it is further 
complicated by factors influencing the severity of the phenotype, such as the 
genetic background and the effect of environment (Stone and Sidow, 2005). 
The study of the impact of mutations on protein structure, stability 
and function may provide a better understanding of the mechanisms of the 
diseases (Gao et al, 2015). Mutations in different types of functional sites will 
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typically have different consequences. About one quarter of the known 
missense SNPs in the human population are significantly deleterious to 
protein function in vivo (Yue and Moult, 2006). There is considerable 
evidence that the most common cause of protein loss-of-function relies on 
changing of the protein’s thermodynamic stability. Most changes lead to 
protein folding equilibrium shifted towards the nonfunctional unfolded state, 
possibly coupled to irreversible aggregation and/or degradation by cell 
degradation’s pathways (Yue et al, 2005; Casadio et al, 2011; Shi and Moult, 
2011; Stefl et al, 2013; Petukh et al, 2015). 
The most common cause of monogenic disease is a single base DNA 
variant resulting in an amino acid substitution and a high fraction of these 
substitutions appear to result in reduction of stability of the corresponding 
protein structure (Yue et al, 2005). Frequently, missense mutations are found 
to destabilize the corresponding protein (Stefl et al, 2013). Destabilizing 
mutations in the core of the protein lead to inactivation of many tumor 
suppressors in cancer. Protein stability is a key characteristic of a functional 
protein (Ramensky et al, 2002 Capriotti et al, 2005; Karchin et al, 2005; Ye 
et al, 2006; Zhang et al, 2011). SNPs can affect the stability of the protein by 
making it susceptible to proteolysis, by changing the thermal inactivation 
temperature or increases the susceptibility of the protein to degradation by 
lysosomal cysteine proteinase, leading to severe reduction in half-life of its 
(Bhattacharya et al, 2017). A change in the amino acid sequence can 
considerably affect protein stability (de Cristofaro et al, 2006; Koukouritaki 
et al, 2007; Ode et al, 2007) through perturbing conformational constraints 
and physicochemical parameters. Mutations involving Cys, Trp, or Pro 
residues are more likely to be disease associated. Cys mutations often involve 
breaking disulfide bridges or forming unwanted disulfide bonds; Trp 
7 
mutations usually significantly destabilize structures and mutations to Pro 
tend to disrupt helical structures (Gao et al, 2015). The degree of 
destabilization was found to be high for mutations that introduce drastic 
changes such as charged to neutral, relatively rigid to relatively flexible, or 
aromatic to aliphatic mutation types. For most of the cases, the 
destabilization was also accompanied by structural changes (Pasquo et al, 
2012; Khan et al, 2013). This observation highlights the difficulties to predict 
the physiological relevance of mutations based on the effect delivered by a 
single methodology. 
A single residue mutation can have effects on protein activity 
(interdicts access to the active site), aggregation (give rise to protein 
aggregation, which is a hallmark of some neurodegenerative diseases, e.g., 
Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic 
lateral sclerosis and prion diseases), binding (can change the affinity of 
binding to partners, such as activators, repressors, or substrates) and 
assembly (change the quaternary structure) (Bhattacharya et al, 2017). 
One of the fundamental problems in protein research is the 
understanding of protein stabilization by complex physical interactions. This 
problem has attracted the attention also in molecular medicine since it has 
been noticed that some diseases such as amyloidosis are likely to be related 
to changes in protein stability due to mutations occurring in the protein 
sequence. In the biomedical context SNPs are very important, as they are the 
most common source of variation in the human genome. Due to the 
redundant nature of the RNA triplet code that encodes proteins, many of 
these SNPs may not cause an amino acid change (synonymous mutations). 
However, when a SNP causes an amino acid change (a non-synonymous 
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mutation) there may be an effect on the structure and function of the encoded 
protein. The protein stability mechanism is studied by using site-directed 
mutagenesis followed by thermodynamic measurements and structure 
determination. Loss of function may lead to disease. It would therefore be 
extremely useful to be able to predict which mutations are likely to cause 
disease. Identifying those SNPs that promote susceptibility or protection to 
complex diseases will aid early diagnosis, prevention and help in finding 
treatments (Worth et al, 2011; Pires et al, 2013). 
The analysis of large datasets of genetic variation can be performed 
with bioinformatics tools to filter the data (Alipoor et al, 2016; Ramensky et 
al, 2002, Shreya et al, 2015, Kalia et al, 2016). Computational methods such 
as SIFT (Ng and Henikoff, 2001; Ng and Henikoff, 2003) Polyphen-2 
(Adzhubei et al, 2013), StructMAn (Gress et al, 2016) or MAPP (Stone and 
Sidow, 2005) classify SNPs according to negative, neutral, or positive effects 
on the structure or function of the protein. Knowledge of the 3D structure of 
a gene product is beneficial in predicting and understanding both function 
and role in disease. However, most studies that analyze the relationship 
between point mutations and experimentally observed 3D protein structure 
published to date have been restricted to individual proteins or single 
diseases. There is a paucity of quantitative analyses of the consequences of 
SNPs on 3D protein structure going beyond the realm of prediction (Arodź 
and Płonka, 2012). 
Genetic variation in the human genome is an emerging resource for 
studying cancer and other diseases (Mueller et al, 2015; Kunz et al, 2016, 
Zang et al, 2016, Didonna et al, 2015). At the protein level, numerous tools 
have been developed to predict the impact of nonsynonymous SNPs on 
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protein function and stability (Yadav et al, 2014; Huang et al, 2015; Casadio 
et al, 2016). These tools usually fall into two categories. The first makes 
predictions based solely on the sequence of a protein, while the second takes 
into account structural information when making predictions (Brown, D. K., 
& Bishop, Ö. T. 2017). Determining which SNPs affect the phenotype would 
help the identification of the molecular mechanisms of disease and 
phenotypic variation (Hepp et al, 2015). There are many other tools to 
differentiate the deleterious or disease-associated SNPs occurring in a gene 
from the neutral or tolerated alterations, and these tools use approaches based 
on different features (Vendruscolo et al, 2003; Hepp et al, 2015). Methods 
based on the structural, physical and chemical properties of the wild type and 
mutant proteins are also available, and allow the identification of the SNPs 
that affect the stability and function of the protein (Ng and Henikoff, 2006; 
Yue and Moult, 2006).  
In order to combine the results of the various tools, consensus 
predictors have been developed to allow comparison between methods that 
use different analytical approaches (Vendruscolo et al, 2003; Bendl et al, 
2014). Studies using combination of different prediction tools have identified 
deleterious mutations in genes involved in different biological processes, 
including, for example, cancer (Hepp et al, 2015). 
Polymorphisms may influence gene transcription, mRNA stability, 
and protein activity. Structural analysis of SNPs in the DNA sequences of 
humans may help to predict an individual’s response to certain drugs, 
susceptibility to environmental factors, and risk of developing particular 
diseases (Johnson et al, 2008; Zhou et al, 2010). SNPs may be also critical 
for personalized medicine, that is a medical model that proposes the 
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customization of healthcare with medical decisions, practices, and/or 
products being tailored to the individual patient. The use of genetic 
information has played a major role in some aspects of personalized 
medicine. 
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Chapter 2 
 
Personalized medicine 
 
SNPs are thought to be critical enablers in realizing the concept of 
personalized medicine and can be highly useful in diagnostics and 
therapeutics development (Markward, 2007). Personalized medicine (PM) is 
defined by the U.S. National Cancer Institute as “a form of medicine that uses 
information about a person's genes, proteins, and environment to prevent, 
diagnose, and treat disease”. The clinical applications of PM in cancer is 
broad, encompassing screening, diagnosis, prognosis, prediction of treatment 
efficacy, patient follow-up after surgery for early detection of recurrence, and 
the stratification of patients into cancer subgroup categories, allowing for 
individualized therapy. PM aims to eliminate the “one size fits all” model of 
medicine, which has centered on reaction to disease based on average 
responses to care (Diamandis et al., 2010). 
Scientific advances since the completion of the Human Genome 
Project have confirmed that the genetic composition of individual humans has 
a significant role to play in predisposition to common diseases and therapeutic 
interventions. The translation of genetic and genomic data into the knowledge 
of patient care for prevention, diagnosis, prognosis and treatment has 
introduced a new paradigm for healthcare: PM. The traditional medicine 
model has relied on best practices emerging from large population studies and 
dictates a one-size-fits-all approach (Bennet et al., 2012). Although 
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synthesized evidence is essential to demonstrate the overall safety and 
efficacy of medical approaches, it falls short in explaining the individual 
variations that exist among patients. Recent advances in genome-wide 
association studies have revolutionized the practice of medicine, causing a 
shift to a patient-centered model (Chouchane et al., 2011) and offering 
tailored diagnostic and therapeutic strategies. 
The field of medicine has seen many new advances in the last several 
decades. An enormous amount of new information has been gained about the 
human genome and the genetic variations between individuals (Diamandis et 
al., 2010). Added to this is the emergence of new technologies for global 
genomic analysis, including high-throughput sequencing, single nucleotide 
polymorphism (SNP) genotyping, and transcript profiling. The construction 
of haplotype maps of the genome (Frazer et al., 2007) is now allowing us to 
view DNA in a much bigger picture than ever before. This, coupled with 
enormous advances in computer systems and bioinformatics, has resulted in a 
revolutionary shift in medical care to the era of PM. The concept of PM is to 
use clinical, genomic, transcriptomic, proteomic, and other information 
sources to plot the optimal course for an individual in terms of disease risk 
assessment, prevention, treatment, or palliation. Thus, PM aims to eliminate 
the “one size fits all” model of medicine, which has mainly centered on 
reaction to a disease (treating the symptoms) based on average responses to 
care, by shifting the emphasis of patient care to cancer prevention and early 
intervention for high-risk individuals (Abrahams et al., 2005; Abrahams and 
Silver, 2009). Moreover, understanding the molecular profiles of individuals 
and how these can cause variations in disease susceptibility, symptoms, 
progression, and responses to treatment will lead to tailoring medical care to 
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fit each individual patient (Ginsburg and McCarthy, 2001; Allison 2008; 
Ginsburg and Willard, 2009). 
Pharmacogenetics and pharmacogenomics deal with the genetic basis 
underlying variable drug response in individual patients. The traditional 
pharmacogenetic approach relies on studying sequence variations in 
candidate genes suspected of affecting drug response. On the other hand, 
pharmacogenomic studies encompass the sum of all genes, i.e., the genome. 
Numerous genes may play a role in drug response and toxicity, introducing a 
daunting level of complexity into the search for candidate genes. The high 
speed and specificity associated with genomic technologies enable the search 
for relevant genes and their variants to include the entire genome (Mancinelli 
et al., 2000). 
Pharmacogenomic analysis can identify disease susceptibility genes 
representing potential new drug targets. All of this will lead to novel 
approaches in drug discovery, an individualized application of drug therapy, 
and new insights into disease prevention. pharmacogenomics may help focus 
effective therapy on smaller patient subpopulations which although 
demonstrating the same disease phenotype are characterized by distinct 
genetic profiles. Moreover, worldwide use of these drugs has revealed 
substantial interindividual differences in therapeutic response. Any given 
drug can be therapeutic in some individuals but less effective in others, and 
some individuals experience adverse drug effects whereas others are 
unaffected. Recognition of interindividual differences in drug response is an 
essential step towards optimizing therapy. Over the past decades, much 
evidence has emerged indicating that a substantial portion of variability in 
drug response is genetically determined, with age, nutrition, health status, 
14 
environmental exposure, and concurrent therapy playing important 
contributory roles. 
Biologists have long accepted that the capacity of organisms to 
respond differently to their environment is genetically determined. Evidence 
of interindividual variations in the response to suxamethonium 
(succinylcholine), isoniazid, and debrisoquine was also scrutinized for a 
genetic connection. Clinical reports first surfaced in the late 1940s of 
peripheral neuropathy occurring in a substantial number of patients treated 
with the antituberculosis drug isoniazid (Hughes et al., 1954). These initial 
clinical observations were followed by the realization that slow metabolizers 
(acetylators), although frequencies varied, followed defined geographic and 
ethnic population distributions (Evans et al., 1960). We now know that the 
"slow acetylator phenotype" represents approximately 40% to 60% of 
Caucasians and results in slow clearance and the potential for associated 
toxicity from drugs such as isoniazid, procainamide, and phenelzine. 
In cancer chemotherapy of acute lymphocytic leukemia, 
administration of drugs such as 6-mercaptopurine, 6-thioguanine, and 
azathioprine can cause severe hematologic toxicity or even death in patients 
possessing nonfunctional ("null") variants of thiopurine methyltransferase 
(TPMT). Each drug after it enters the body interacts with numerous proteins, 
such as carrier proteins, transporters, metabolizing enzymes, and multiple 
types of receptors (Sadee, 1998; Sadee 1999; Evans and Relling, 1999). 
These proteins determine drug absorption, distribution, excretion, target site 
of action, and pharmacological response. Moreover, drugs trigger 
downstream secondary events that may also vary among patients. As a result, 
multiple polymorphisms in many genes may affect drug response, requiring a 
15 
genome-wide search for the responsible genes. Profiling the expression 
pattern of genes in a target tissue reveals mechanisms of drug action in a 
genomic context, and it can serve to clarify interindividual differences in 
drug response that are downstream of immediate drug effects in the body. 
“The Human Genome Project and advanced technology spin-offs 
emanating from it will have a profound impact on drug discovery, 
development, and therapy within the pharmaceutical industry” (Schachter, 
1998). With the completion of the human genome project at the beginning of 
the 21st century, the biological sciences entered an unprecedented age of data 
generation, and made its first steps toward an era of personalized medicine 
(Brown, D. K., & Bishop, Ö. T. 2017). Since then, the world has embarked 
on a revolution in science and healthcare that is changing the way we live and 
carries the promise of individualizing clinical delivery to improve health, and 
prevent and cure human disease (Thomas et al, 2016). Innovative automated 
instrumentation, new analytical and informatics approaches, and novel 
strategies emerging from genome-based research will be essential for 
exploiting the massive primary sequence data. Genomic techniques are 
making it possible not only to identify tangible new gene targets for drug 
discovery efforts, but also to find associations between specific genetic 
markers and drug response in a patient population. Technical innovations 
such as DNA microarrays and microfluidic analytical devices are remodelling 
the biological sciences by enabling economy of scale for high-throughput 
DNA sequencing and gene mapping required for genomic research. 
An evolving key element in genome-wide searches for genes relevant 
to disease and therapy is a comprehensive map of polymorphisms distributed 
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over the entire genome (Gonzaga-Jauregui et al, 2012, Tuxen; I. V et al, 
2014; Karki et al, 2015). 
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Chapter 3 
 
Defective protein variants 
 
Any nsSNP can be deleterious either because it leads to disruption of a 
site that is directly involved in the function of a protein (e.g. a catalytic 
residue, a residue involved in ligand binding or a residue that forms a critical 
interaction with another protein), or because it causes destabilization of the 
protein structure. Both events can promote protein degradation or severe 
changing in protein function due to loss of the structural framework. The 
prediction of the consequences of nsSNPs, in order to discriminate neutral 
variants from those causative of a pathological phenotype, is a major research 
challenge as the rapid growth of genomic tools has produced a vast amount of 
information about genetic variation among individuals (Karchin 2009; 
Mooney 2005; Ng and Henikoff 2006; Cardoso et al, 2015). In order to have 
the greatest medical impact we must be able to separate genuine disease-
causing or disease- associated genetic variants from the broader background 
of variants present in all human genomes that are rare, potentially functional 
but not actually pathogenic for the disease (MacArthur et al, 2014). 
The importance of studying of protein folding and stability is 
manifested by the fact that protein misfolding is involved in many diseases 
(Dobson, 2003; Valastyan and Lindquist, 2014). Proteins consist of an 
elaborate arrangement of interior folds that collapse into a final 
thermodynamically stable structure and, for many proteins, only a modest 
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free- energy gain (Lindquist and Kelly, 2011) is associated with correct 
folding of a protein compared with its innumerable potential misfolded states. 
The problem of how protein misfolding is promoting certain types of 
insoluble fibrillar aggregates, at the basis of several amyloid disorders, has 
been documented in vitro and a list of putative residue mutations causing 
protein aggregates is available (Chiti and Dobson, 2009; Naiki and Nagai, 
2009; Uversky, 2008). Other human diseases different from amyloidosis have 
been proposed to be related to protein misfolding (Thusberg and Vihinen, 
2009; Groenendyk et al, 2010). 
Research on protein misfolding and aggregation is progressively 
gaining attention, largely because of its impact on the understanding of the 
molecular mechanisms underlying widespread pathologies involving amyloid 
formation such as Alzheimer’s (Selkoe 1996) or Parkinson’s (Trojanowski 
and Lee 1998) disease. Aggregation is a common undesirable event for 
polypeptide chains, involving the irreversible interaction of two or more 
denatured protein molecules leading to precipitation of protein. Missense 
mutations that trigger protein aggregation have been shown to be associated 
with an increasing number of pathologies (Guijarro et al, 1998; Chiti et al, 
1999; Fandrich et al, 2001; Chiti et al, 2003; Bucciantini et al, 2004; Harris 
and True 2006; Keage et al, 2009; Khemtemourian et al, 2008; Robinson, 
2008; Yankner and Lu 2009). 
Some genes for rare, heritable Mendelian disorders have been 
identified, in which variation of single gene is both necessary and sufficient 
to cause disease (Hamosh et al, 2005). On the other hand, complex polygenic 
diseases are much more complicated to be directly related to gene variation 
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since they are thought to be due to the combined effect of many different 
susceptibility such as genetic variants and environmental factors 
(multifactorial diseases). Small genetic changes may be responsible for 
medicinal drug delivery and disease susceptibility, which have already been 
verified in some diseases, such as diabetes mellitus and cancer (Chung and 
Chanock, 2011; Vieira et al, 2011). 
Cancer 
Cancer is a heterogeneous group of diseases characterized by 
uncontrolled growth of the cells. Cancers are generally classified by the type 
of cells or organ from which they originate. Since malignant growth can 
occur in virtually all locations of the body, there are over 100 different types 
of cancers. Cancer is an immensely complex and diverse disease; however, a 
set of characteristics are shared among almost all malignancies. Those 
characteristics, named hallmarks of cancer, are a unified set of capabilities 
that are acquired during tumorigenesis. The hallmarks of cancer are self- 
sufficiency in growth signals, insensitivity to growth-inhibitory signals, 
evasion of programmed cell death, limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg, 
2000). The list has been further extended with emerging hallmarks such as 
deregulating cellular energetics and avoiding immune response. Additionally, 
enabling characteristics were proposed, which are tumor promoting 
inflammation, and genome instability and mutation (Hanahan and Weinberg, 
2011). Cancer is an important health problem worldwide and it is one of the 
most frequent causes of death. Cancer is now becoming the first cause of 
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death in developed countries and the second in developing countries (Jemal 
et al, 2011). 
Several types of cancer can be caused by environmental factors, 
which can lead to cancer by inducing DNA damage (Levi et al, 1999). Even 
though the exact onset and development of cancer have not been identified, it 
is determined that genetic susceptibility plays an important role on disease 
etiology (Lichtenstein et al, 2000). In cancer research, genetic aspects have 
become even more important for revealing the molecular basis of the disease 
that may have a predictive value in cancer development and may contribute 
to forecast the efficacy of treatment. Personalized therapies are under 
development, such as anticancer vaccination and viral gene therapy of cancer 
by adenovirus particles (Hall et al, 2010). Cancer resistance to drugs is of 
paramount importance when evaluating the response to chemotherapy; 
therefore, its relevance is unambiguous in clinical practice (Valera et al, 
2004). 
SNPs are the most common genetic causes of drug resistance 
(Cascorbi, 2006; Chou Dhuri and Klaassen, 2006). SNPs may lead to 
different network of protein interactions in signal transduction pathways 
(Effert and Volm, 2005). Resistance can also be caused by SNPs of 
membrane transporters (Cascorbi, 2006; Choudhuri and Klaassen, 2006). A 
detailed study of proteins associated with SNPs and involved in cancer may 
lead to a better understanding of the biological mechanism for cancer to 
improve prevention, early detection and treatment. 
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Chapter 4 
 
Aim of the study 
 
Mutations can frequently affect several protein biophysical parameters 
simultaneously and may or may not cause diseases (Gong et Blundell, 2010). 
There are many prediction studies on the effect of nsSNPs on protein stability. 
Computational analysis has predicted that around 30% of protein variants 
resulting from nsSNPs are less stable than the wild type, however 
experimental studies on the effect of mutations on protein structure, stability 
and function are still needed. Indeed, experimental studies have been carried 
out on very few proteins (Gao et al, 2015). These experimental stability 
studies, that require mutagenesis, protein expression and purification followed 
by thermal and chemical unfolding, are difficult to perform due to the cost and 
time needed for the entire process. 
This study is focused on the comparison of the structural, biochemical 
and biophysical parameters between a wild-type protein and the single 
nucleotide variants found in pathological tissues. We have identified several 
nsSNPs related to pathological states in humans, such as cancer, and used site-
directed mutagenesis to produce recombinant mutant proteins in E.coli cells. 
The variants carrying missense mutations, identified in pathological human 
tissues have been characterized and compared with the wild-type proteins in 
order to investigate whether the amino acid substitutions affected protein 
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conformational stability and interactions with ligand or inhibitors. We 
analyzed the effects induced by nsSNPs on protein structure and function, by 
means of structural stability, binding and activity studies. In particular, we 
selected variants from OMIM (Hamosh et al, 2005) and COSMIC (Forbes et 
al, 2010) databases for somatic mutations in cancer that store information 
about genetic variations and aim to collect mutations in all genes. Our study 
may provide information also on the rational basis for personalized medicine 
since SNPs may be linked to individual susceptibility either to develop 
disease or to drug response (Aneesh et al, 2009). 
The proteins selected for this study, are: 
• Peroxisome proliferator-activated receptor (PPARγ) a nuclear 
receptor in the superfamily of ligand inducible transcription factors. 
PPARγ plays crucial role within the cell, it is an important regulator of 
adipocyte differentiation and lipid metabolism. It promotes cell 
differentiation in hepatocytes, fibroblasts, myocytes, colon epithelium, 
and in adipocytes (Varga et al, 2011) role in lipid metabolism, PPARγ 
has been reported to be involved in several processes related to cellular 
differentiation and development and to carcinogenesis (Wang T et 
al,2006). Recent studies have indicated PPARγ related also to 
cardiovascular disease, chronic inflammation, neurodegenerative 
disorders and cancer (Menendez-Gutierrez MP et al, 2012). The genes 
activated by PPARγ stimulate lipid uptake in adipocytes and initiate 
adipogenesis (Anghel SI, et al. 2007). 
Here we selected nine nsSNPs variants of the PPARγ ligand binding 
domain, V290M, R357A, R397C, F360L, P467L, Q286P, R288H, 
E324K, and E460K, expressed in cancer tissues and/or associated with 
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partial lipodystrophy and insulin resistance. Our purpose is to study the 
effects of single amino acid substitution on PPARγ variants: 
thermodynamic stability, spectral properties, molecular dynamics and 
transcription activity have been investigated. The molecular dynamics 
simulated the movements and trajectories of all the atoms in these 
structures over a limited period of time. It can be used to explore the 
protein structure upon single amino acid substitution to obtain 
information about protein flexibility and dynamics (Brown, D. K., & 
Bishop, Ö. T. 2017). 
 
In this project we also will investigate the effects of PPARγ wild-type 
and its variants in eukaryotic cell line in order to see if adipogenesis 
pathway and some cancer related markers are differently expressed. 
Detailed Western blot analysis will be performed after cell transfection 
either with PPARγ wild-type and variants in order to see the expression 
level of the proteins. For this study, we have selected those variants that 
showed the most significant differences in term of stability and structure 
in solution and in dynamics. Two interesting variants have been selected 
for studies in eukaryotic cell lines: E324K and R397C. Both residues, 
E324 and R397, are involved in one of the two salt bridges that may 
contribute to PPARγ stabilization. 
 
Our purpose is to combine the structure and function relationship on 
natural occurring variants studied in vitro, with the results obtained in 
eukaryotic cell lines. The in vitro studies will let us explore the effect of 
the mutation on the protein structure and stability when compared with 
the wild type enzyme. On the other hand, the eukaryotic cell line studies 
will give us the chance to investigate how biochemical pathways are 
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modified in the presence of the variants and how they affect cell 
differentiation, cell death and apoptosis. 
 
The analysis of the effect of PPARγ mutations on important pathways for 
the eukaryotic cells, such as cellular differentiation, apoptosis, propensity 
to tumorigenicity and adipogenesis (Farmer, S. R. 2005; Wang et al, 
2013) may help in understanding the connection between mutation and 
disease. Indeed, the disruption of cellular pathways may result in the 
development of several diseases and pathological states (Subbarayan et 
al, 2004). nsSNPs can also result in altered levels of expression of 
proteins and mRNAs and may induce functional alteration of the 
biological properties of the proteins, so biochemical analysis of the 
cellular properties of polymorphisms are necessary to understand the 
impact of the mutations on the biological function of the proteins (Guo et 
al, 2016). 
 
• Bromodomains (BRDs) are the only known protein recognition module 
that selectively targets ε-N-acetylation of lysines. Acetylation of lysine 
residues (Kac) is one of the most frequently occurring post-translational 
modifications which controls gene transcription and a vast array of 
diverse cellular functions. Deregulation of lysine acetylation levels has 
been associated with the development of many diseases, such as cancer, 
and enzymes regulating acetylation have emerged as interesting targets 
for drug discovery. In this study we selected some BRDs variants found 
in cancer tissues and we analyzed the effects of a single amino acid 
change on BRDs thermodynamic stability, spectral properties and the 
interaction with inhibitors JQ1 and PFI-1. 
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• Phosphoglycerate kinase (PGK), an essential enzyme that catalyzes the 
reversible phosphotransfer reaction from 1,3-bisphosphoglycerate (1,3- 
BPG) to MgADP to produce 3-phosphoglycerate (3-PG) and MgATP, an 
important ATP-generating step in glycolysis. Several solid tumors 
exhibit an increased expression of glycolytic enzymes such as PGK1 to 
generate ATP in hypoxic conditions. The elevated levels of PGK1 
protein, detected in the serum of patients affected by pancreatic cancer 
(Hwang et al., 2006; Sun et al., 2015) and in breast cancer tissues (Sun et 
al., 2015), suggest a plausible role of PGK1 as a cancer biomarker. In 
this study we selected the variants R38M, R65W, G166D, M189I, 
A199V, V216F and F241S associated to human carcinoma. We are 
generating recombinant protein in order to analyze the consequences of 
the mutations on PGK1 thermal and thermodynamic stability and the 
kinetic activity. 
 
A detailed investigation at the molecular and cellular level of natural 
protein variants may provide useful information for the development of 
new therapeutic strategies, particularly in the search of small molecules 
able to selectively interact with the variants, which is an essential 
preliminary step to personalized medicine.  
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Chapter 5 
 
Peroxisome Proliferator Activated 
Receptor (PPARγ) 
 
Peroxisome proliferator-activated receptors (PPARs) are members of 
the nuclear hormone receptor superfamily of ligand-activated transcription 
factors that regulate a large number of gene networks involved in cell 
metabolism, growth, differentiation, and inflammation (Picard et al, 2002; 
Lefebvre et al, 2006). There are three PPAR isoforms, α, β, and γ whose 
expression patterns vary among tissues. PPARs are a family of nuclear 
transcription factors that interact with PPAR response elements in controlling 
growth-regulatory gene expression (Vamecq et al, 1999). PPARs belong to the 
steroid hormone receptor superfamily and are involved in ligand-inducible 
lipid metabolism (Issemann et al, 1990). Prostanoids and their synthetic 
analogues and other long-chain fatty acids and their metabolites act as ligands 
for the three PPARs, α, β, and γ (Issemann et al, 1990; Tontonoz et al, 1994). 
The PPARγ selective ligand 15-deoxy- D12,14-prostaglandin J2 (15d-PGJ2) 
is produced in large amounts in the prostate gland via spontaneous conversion 
from prostaglandin D2 (Tokugawa et al, 1998). Another PPARγ ligand, 15- 
hydroxyeicosatetraenoic acid (15-HETE), is produced in normal epithelial 
cells (ECs) by 15-lipoxygenase-2 (15-LOX-2) (Shappell et al, 1999; Tang et 
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al, 2002). These PPARγ ligands, 15d-PGJ2 and 15-HETE, are likely to be 
involved in prostate carcinogenesis. 
PPARγ is a human transcription factor whose activity is regulated by 
direct binding of lipid metabolites, and xenobiotics (Chawla et al, 2001). 
Agonist ligand binding (eicosanoids, prostaglandins and synthetic agonists), 
by promoting the stabilization of the PPARγ active conformation of the C- 
terminal activation function-2 helix (H12), triggers the recruitment of co- 
activator proteins that locally remodel chromatin and activate the cellular 
transcriptional machinery. The resulting protein complexes activate the 
transcription of specific target genes thus inducing intracellular signalling 
cascades that mediate the physiological effects of the ligands. In the absence 
of ligand, PPARγ has the potential to actively silence genes to which it is 
bound by recruiting transcriptional corepressor complexes containing nuclear 
receptor corepressor (N-CoR) or SMRT (silencing mediator of retinoid and 
thyroid receptors) containing histone deacetylase (HDAC) activity that 
represses the transcription of the target gene (Guan et al, 2005). 
Nuclear receptor ligands bind in a cavity within a moderately 
conserved ligand binding domain (LBD) toward the C terminus of the 
nuclear receptor. A linker joins the LBD to the central DNA binding domain 
of the receptor. The LBDs of receptors have a conserved structure that 
consists of three layers of α-helices. The central layer is incomplete, leaving a 
cavity that can accommodate ligand. The size of this cavity varies according 
to the disposition of the helices in the outer layers. The ligand binding cavity 
in PPARγ is particularly large. Nuclear receptors activate transcription in 
response to ligand binding through the displacement of co-repressor proteins 
and the recruitment of coactivator proteins. The mechanism seems to involve 
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both a global stabilization of the LBD on ligand binding as well as a specific 
stabilization of the C-terminal helix 12 (Kallenberger et al, 2003). Notably, 
various partial agonists were shown to differentially stabilize distinct regions 
of the LBD (Bruning et al, 2007). The modulation of PPARγ activity may be 
ascribed to the modification of the conformation of the loop following helix 
2’ (Waku et al, 2009). Once bound to ligand, PPARγ binds coactivators in a 
helix 12– dependent fashion, resulting in a transcriptionally active complex. 
Given the importance of PPARγ as a transcription factor regulating key 
physiological processes and as a drug target for insulin sensitizers, many 
structures have been determined in complex with various synthetic agonists 
and with natural ligands (Cronet et al, 2001; Itoh et al, 2008; Montanari et al, 
2008). 
Ligand-activated PPARs form heterodimers with the 9-cis retinoic 
acid receptor (RXR-α) and bind to peroxisome proliferator response elements 
(PPRE) in the promoter regions of target genes to stimulate their expression 
(Bardot et al, 1993; Tontonoz et al, 1994). PPARγ activation can inhibit the 
activity of other pro-inflammatory transcription factors through 
transrepression mechanisms (Pascual et al, 2005). PPARγ is expressed in 
numerous cells including pulmonary vascular endothelial and smooth muscle 
cells where it plays a critical role in normal pulmonary vascular function (Lu 
et al, 2013; Green et al, 2012; Green et al, 2011). 
There are two PPARγ isoforms, PPARγ 1 and PPARγ 2. Some 
cancers have been shown to express PPARγ (Segawa et al, 2002; Nwankwo 
et al, 2001  ¸ Mueller et al, 2000; Kubota et al, 1998) and prostate cancer 
expresses significantly more PPARγ than normal cells (Segawa et al, 2002; 
Nwankwo et al, 2001; Kubota et al, 1998). Investigators also have reported 
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the inhibitory effects of PPARγ agonists on prostate cancer cells (Kubota et 
al, 1998; Mueller et al, 2012; Butler et al, 2000; Shappell et al, 2001). 
PPARs are implicated in tumor progression, cellular differentiation, 
and apoptosis. Hence, modulation of their function is considered as a 
potential target for cancer prevention and treatment. Notably, PPAR 
functions have been related to various pathologies, ranging from metabolic 
disorders to cardiovascular disease, chronic inflammation, neurodegenerative 
disorders and cancer (Menendez-Gutierrez et al, 2012; Peters et al, 2012). 
PPARs ligands and other agents, influencing PPAR signalling pathways, 
have been shown to display chemopreventive potential by mediating tumor 
suppressive activities in a variety of human cancers and could represent 
potential novel targets to inhibit carcinogenesis and prevent tumor 
progression (Renaud et al, 2000). In addition, PPARγ agonists have been 
recently reported to lower the incidence of a number of neurological 
disorders (Chen et al, 2012). 
PPARγ is highly expressed in cancer tissues, such as gastric, 
colorectal, prostate and ovarian cancer (Subbarayan et al, 2004; Segawa et 
al., 2002; Zhang et al., 2005; Yao et al., 2010; Pang et al.,2015), and plays a 
crucial role in carcinogenesis (Han and Roman, 2007). In gliomas cells, 
PPARγ is downregulated, leading to a decrease in insulin sensitivity and an 
increase in neuroinflammation. Moreover, PPARγ contributes to regulate 
some key circadian genes. Abnormalities in the regulation of circadian 
rhythms and dysregulation in circadian clock genes are observed in gliomas. 
Circadian rhythms are dissipative structures, which play a key role in far-
from- equilibrium thermodynamics through their interactions with 
WNT/beta- catenin pathway and PPARγ. In gliomas, metabolism, 
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thermodynamics, and circadian rhythms are tightly interrelated (Vallèe et al, 
2017). 
Some studies suggested that PPARγ had an anti-cancer effect through 
the inhibition of tumor growth, induction of cell differentiation and apoptosis 
(Shimada et al., 2002). It also affects tumorigenesis by modulating the 
expression of its target genes (Leung et al., 2004). However, the underlying 
mechanism of PPARγ on antitumor is not completely clear until now (Guo et 
al, 2016). Recently, some studies reported that PPARγ can regulate 
amyloidogenic pathways (D’Abramo et al, 2005; Sastre et al, 2006), they 
suggest that PPARγ may be a potential candidate gene for Alzheimer’s 
disease. However, results on association between PPARγ and late-onset 
Alzheimer’s disease were inconsistent yet (Helisalmi et al, 2008; Wu et al, 
2015; Zhang et al, 2017). In addition, recent studies have indicated PPARγ 
agonists have anti- fibrogenic properties in organs besides the gut; however, 
their effects on human intestinal fibrosis are poorly understood (Koo et al, 
2017). 
The regulation of glucose metabolism and fatty acid storage is one of 
the most significant PPARγ activity. PPARγ is the target of many drugs used 
in the treatment of type 2 diabetes. The anti-diabetic thiazolidinediones 
(TZD) activate PPARγ and are efficient drugs against type 2 diabetes, despite 
the occurrence of several adverse effects that confirms the abundant 
pleiotropic actions of PPARγ (Menendez-Gutierrez et al, 2012). Notably, the 
marketed TZD class of antidiabetic agents binds to and activates PPARγ. 
These drugs enhance insulin sensitivity in target tissues and lower glucose 
and fatty acid levels in type 2 diabetic patients. However, despite their proven 
benefits, these drugs have been plagued by certain adverse effects: weight 
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gain, higher rate of bone fractures, fluid accumulation, and pulmonary 
edema. A detailed structural investigation of the PPARγ interaction with new 
compounds may lead to the development of new class of drugs targeting lipid 
and glucose metabolism regulation (Pochetti et al, 2010). 
There is evidence that some rare missense mutations in PPARγ have 
profound phenotypic effects in affected individuals, contributing to the risk 
of dyslipidaemia and type 2 diabetes (Chan et al., 2013) and colon cancer 
(Barroso et al., 1999; Savage et al, 2003; Meirhaeghe & Amouyel, 2004; 
Agostini et al, 2006; Semple et al, 2006; Tan et al, 2008; Jeninga et al, 2009). 
Some of these mutations in PPARγ have been related to lypodistrophy and 
insulin resistance (Jeninga et al, 2009; Visser et al, 2011), although the 
molecular mechanism by which these mutations act is not clear. Many of 
these variants are nsSNPs, single nucleotide variations occurring in the 
coding region and leading to a polypeptide sequence with amino acid 
substitutions (Dixit et al, 2009). Expression and structural characterization of 
the PPARγ variants associated with energy metabolism disorders, 
carcinogenesis and tumour progression may increase our knowledge about 
the molecular interactions in PPARs related disease by studying the effects of 
these mutations on PPARγ conformational stability and binding interactions. 
We studied the effect of the human PPARγ F360L mutant associated with 
familial partial lipodystrophy (Al-Shali et al, 2004) on PPARγ thermal 
stability, binding interaction and structure. The structure solution of PPARγ 
F360L revealed the structural reason for its defective behaviour and for the 
significant decrease of functional activity and binding to synthetic ligands 
(Lori et al, 2014). 
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This study is focused on nsSNP variants of the ligand binding domain 
(LBD) of PPARγ a nuclear receptor in the superfamily of ligand inducible 
transcription factors that play an important role in regulating lipid 
metabolism and in several processes ranging from cellular differentiation and 
development to carcinogenesis. Here we selected nine nsSNPs variants of the 
PPARγ ligand binding domain, V290M, R357A, R397C, F360L, P467L, 
Q286P, R288H, E324K, and E460K, expressed in cancer tissues and/or 
associated with partial lipodystrophy and insulin resistance. The effects of a 
single amino acid change on the thermodynamic stability of PPARγ, its 
spectral properties, molecular dynamics and transcription activity have been 
investigated. 
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Chapter 6 
 
Bromodomains 
 
Bromodomains (BRDs) dysfunction has been linked to the onset and 
development of several diseases (Müller et al, 2011). BRDs are the only 
known protein recognition module that selectively targets ε-N-acetylation of 
lysines. Acetylation levels are reversibly maintained by a group of enzymes, 
the histone acetyl-transferases (HATs) and histone deacetylases (HDACs) that 
“write” and “erase” acetylation marks on histones. To date little is known of 
the “reading” process of Kac that involves BRDs. Kac is recognized by a 
central hydrophobic cavity and is anchored by a hydrogen bond with an 
asparagine residue present in most BRDs. However, the substrates (e.g. the 
acetylated sequences that are specifically recognized) of most BRDs are 
largely unknown. Proteins that contain BRDs have been implicated in the 
development of a large variety of diseases (Filippakopoulos and Knapp, 
2014). 
A comprehensive study of the BRDs variants associated with 
carcinogenesis and tumour progression may increase our knowledge about 
the molecular interactions in BRDs related disease by studying the effects of 
these mutations on BRD conformational stability and binding interactions. 
The aim of this study is the expression and structural characterization of the 
BET BRDs wild-type and variants carrying missense mutations and related to 
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pathological states in humans to investigate whether these mutations affect 
BRDs conformational stability and interactions with inhibitors. 
The human proteome encodes over 40 proteins that contain more than 
60 diverse BRDs (Filippakopoulos and Knapp, 2012). Despite their low 
sequence identity, all BRDs share a conserved fold comprising a left-handed 
bundle of four alpha helices, linked by diverse loop regions that contribute to 
substrate specificity. The conserved BRD fold contains a deep, largely 
hydrophobic acetyl lysine binding site, which represents an attractive pocket 
for the development of small, pharmaceutically active molecules. 
The inhibitors that specifically target the BET proteins selectively 
interfered with gene expression that mediated cellular growth and evasion of 
apoptosis in cancer (Dawson et al, 2011; Delmoreet al, 2011; Zuber et al, 
2011). BET proteins belong to the subfamily II of BRDs, sharing a common 
architecture comprising two N-terminal BRDs that exhibit high level of 
sequence conservation as well as an extra-terminal (ET) domain and a more 
divergent C-terminal recruitment domain. There are four proteins in this 
subfamily, BRD2, BRD3 (LeRoy et al, 2008), BRD4 (Ullah et al, 2008) and 
BRDT (Moriniere et al, 2009).  
BRD2 contains two domains (BD1 and BD2), which are considered to 
be responsible for binding to acetylated chromatin. It is ubiquitously 
expressed in mammalian tissues. 
Importantly, BET-BRDs stay associated with chromatin during 
mitosis. This unique feature of the BET proteins is utilized by papilloma and 
Kaposi’s sarcoma-associated herpesviruses for tethering their genomes to the 
mitotic chromosome of their host, resulting in viral propagation during the 
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cell division. BRD2 has been shown to bind to the transcription factor E2F, 
but also co-activator TAFs, members of the SWI/SNF complex, HATs and 
HDACs (histone deacetylases) to regulate the expression of diverse genes 
(Nakamura et al, 2007). BRD2 can function either as a transcriptional co-
activator or co-repressor, depending on the specific promoter and cellular 
context and has been shown to regulate the expression of cyclin A. 
Constitutive over-expression of BRD2 in the B-cells of transgenic mice 
results in the development of B-cell lymphoma and leukaemia. BRD3 
contains two bromodomains (BD1 and BD2) and is ubiquitously expressed in 
human adult and fetal tissues, with highest expression in testis, ovary, 
placenta, uterus, and brain. BRD3 expression is induced in activated 
lymphocytes and it is highly expressed in undifferentiated embryonic stem 
(ES) cells whereas expression levels are reduced upon endothelial 
differentiation (Ishii et al, 2005). Bromodomains in BRD4 (BD1 and BD2) 
bind to specific acetylated lysines in histones H3 and H4 and BRD4 has been 
isolated in complex with the replication factor complex. Mouse embryos 
nullizygous for BRD4 are non-viable due to an early post-implantation 
defect, suggesting that BRD4 is required for fundamental cellular processes 
(Houzelstein et al, 2002).  
In our study we selected three of the four BET proteins BRD2, BRD3 
and BRD4, that belong to the subfamily II of BRDs. Wild type and variants 
of BRD2(1), BRD4(1), BRD2(2), BRD3(2) and BRD4(2) have been studied 
in order to investigate the effect of amino acid substitutions on their structure 
in solution and on their thermal and thermodynamic stability. The interaction 
with inhibitors JQ1 and PFI-1 was investigated by isothermal titration 
calorimetry experiments (ITC). 
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Chapter 7 
 
Phosphoglycerate kinase 
 
Phosphoglycerate kinase (PGK) (EC 2.7.2.3) is an essential enzyme 
for all living organisms. It catalyzes the reversible phosphotransfer reaction 
from 1,3-bisphosphoglycerate (1,3-BPG) to MgADP to produce 3-
phosphoglycerate (3-PG) and MgATP, an important ATP-generating step in 
glycolysis. Human PGK can phosphorylate L-nucleoside analogues, which are 
used in antiviral and anticancer therapies (Krishnan et al, 2003; Gallois-
Montbrun et al, 2004; Gondeau et al, 2008). PGK was also shown to 
participate in the DNA replication and repair in mammal cell nuclei (Jindal et 
al, 1990). Finally, extracellular PGK has been recently reported to exhibit 
thiol reductase activity on plasmin, leading to angiostatin formation, which 
inhibits angiogenesis and tumor growth (Lay et al, 2000; Shichijo et al, 2004). 
PGK is a typical hinge- bending monomeric enzyme containing N- and C-
terminal domains. The N- terminal domain binds 3-PG or 1,3-BPG, whereas 
the C-terminal domain binds MgADP or MgATP. The two domains are 
separated by a deep cleft and linked by two alpha-helices (α-helix 7 and α-
helix 14) (Vas et al, 2010; Palmai et al, 2009). 
Two human phosphoglycerate kinase isoenzymes, PGK1 and PGK2, 
have been so far identified, characterized by distinctive tissue localization and 
encoded by two distinct genes (Willard et al, 1985; McCarrey et al, 1987). 
PGK1 is ubiquitously expressed in all somatic cells. PGK2, also known as 
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testis form, is unique to meiotic/postmeiotic spermatogenic cells. PGK1, in 
addition to its metabolic function, may play different roles. This enzyme may 
be secreted in the extracellular environment by tumor cells and act as a thiol 
reductase regulating angiogenesis (Wang et al., 2007). In addition, 
translocation of PGK1 to the nucleus is related to binding to alpha DNA 
polymerase (Boukouris et al., 2016). Under hypoxic conditions, PGK1 may 
translocate from cytoplasm to mitochondrion where it may act as a protein 
kinase and phosphorylate different protein substrates (Li et al., 2016). 
Recently, the protein kinase activity of PGK1 has been related to initiation of 
autophagy (Qian et al., 2017). 
Several somatic mutations of PGK1 have been identified in different 
cancer types, as reported in COSMIC (Catalogue of Somatic Mutations in 
Cancer) (http://cancer.sanger.ac.uk/cosmic) (Forbes et al., 2011). Different 
mutations of the PGK1 gene have been so far identified and the reasons for 
the phenotypic variability associated with mutations are still unknown 
(Chiarelli et al, 2012).  
In our study we selected some PGK1 mutations found in cancer 
tissues and annotated in the COSMIC database and we report the effect of 
these variants analyzing the structure, the conformational stability, the 
protein folding and the kinetic behaviour compared with its wild-type 
counterpart. We selected seven PGK1 variants (R38M, R65W, G166D, 
M189I, A199V, V216F and F241S) associated to human carcinoma. We are 
generating recombinant protein for each of the identified mutants using site 
directed mutagenesis and available bacterial expression systems. Introduction 
of these mutations results in soluble recombinant protein and allows to study 
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the consequences of the mutations on PGK1 thermal and thermodynamic 
stability and the kinetic activity. 
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Chapter 8 
 
Results and discussion 
 
SNPs are the most frequent form of human genetic variation (Dunham 
et al, 2012) occurring, on average, approximately every 1200 base pairs (Stefl 
et al, 2013) nsSNPs occur in the DNA coding region and lead to an amino 
acid change in the protein, missense mutation, that is interesting in medical 
biology because it may affect protein function and lead to pathogenic 
phenotypes (Thusberg et al, 2009; Li et al, 2012; Sun et al, 2010). 
Furthermore, nsSNPs have been shown to be related to drugs sensitivity 
suggesting new therapeutic personalized strategies. 
Several natural variants are associated with the development of 
diseases and have been catalogued in several databases such as OMIM 
(Hamosh et al, 2005), the Human Gene Mutation Database (Stenson et al, 
2008) and COSMIC (Forbes et al, 2011). 
In most of the cases the SNPs stability has been considered to be 
responsible of the mutations impact on the pathological conditions or on the 
genetic susceptibility to diseases of the individuals. The most common cause 
of protein loss of function is the destabilization of its native structure (Pasquo 
et al, 2012; Lori et al, 2013) and SNPs have been reported to affect protein 
folding and to produce changes in thermodynamic stability (Adhikari et al, 
2015; Kroncke et al, 2015). Experimental studies on thermal and 
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thermodynamic stability of some natural protein variants expressed in cancer 
tissues revealed a decrease in thermal stability and an increase of protein 
flexibility (Pasquo et al, 2012; Lori et al, 2013; Rowling et al, 2010). 
Understanding the functional consequences of nonsynonymous 
changes, and predicting potential causes, involves integration of information 
from multiple heterogeneous sources, including sequence, structural data and 
pathway relations between proteins, and the molecular basis of diseases. 
nsSNPs may influence an individual’s susceptibility to disease -or response 
to drugs- through their impacts on a protein’s structure and hence cause 
functional changes. The future of SNP analysis greatly lies in the 
development of personalized medicines that can facilitate the treatment of 
disorders induced by genomic variations. Personalized medicine is a medical 
model that proposes the customization of healthcare with medical decisions, 
practices, and/or products being tailored to the individual patient. The 
knowledge of SNPs will help in understanding pharmacokinetics or 
pharmacodynamics and how drugs act in individuals with different genetic 
variants. Diseases with different SNPs may become relevant 
pharmacogenomic targets for drug therapy. 
PPARγ 
In this study we selected nine nsSNPs variants of the PPARγ ligand 
binding domain, V290M, R357A, R397C, F360L, P467L, Q286P, R288H, 
E324K, and E460K, expressed in cancer tissues and/or associated with partial 
lipodystrophy and insulin resistance. The effects of a single amino acid 
change on the thermodynamic stability of PPARγ, its spectral properties, and 
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molecular dynamics have been investigated. The nsSNPs PPARγ variants 
show alteration of dynamics and tertiary contacts that impair the correct 
reciprocal positioning of helices 3 and 12, crucially important for PPARγ 
functioning. 
PPARγ, a nuclear receptor that belongs to the ligand-dependent 
transcription factors, consists of a central DNA binding domain and a 
carboxy- terminal domain involved in ligand binding, dimerization, and 
transactivation. PPARγ adopts an active conformation that promotes 
transcription upon heterodimerization with RXR in the presence of a ligand. 
The ligand binding site is buried within the core of the LBD, which is folded 
into three layers of α-helices. The selection of the variants was focused on 
those mutations located in putatively critical positions of the LBD, such as 
Q286P, R288H, V290M, E324K, E460K, and P467L, in close proximity to 
the residues involved in ligand binding. We also considered those non-
conservative amino acid substitutions leading to alteration of the polarity of 
the residue, such as E324K, E460K, R357A, and R397C, or in the secondary 
structure propensity, as in the case of Q286P. The thermodynamic 
parameters, measured by monitoring the secondary structure changes by far-
UV circular dichroism in the apparent two- state urea-induced unfolding 
transitions, are similar for all variants, and only slightly different with respect 
to the wild type, with the exception of F360L. On the other hand, the tertiary 
structure changes monitored by fluorescence reveal a complex non two-state 
process and significant differences among the natural variants. The analysis 
of the thermodynamic parameters obtained by fitting the fluorescence 
changes to a three-state unfolding reveals a decreased stability of the native 
state for all variants except for R288H and V290M. Interestingly, the variants 
P467L and Q286P show a destabilization of both the native and the 
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intermediate state. Both amino acid substitutions involve a proline residue 
and, in the case of Q286P, a residue located in the middle of H3. All variants 
show a slight decrease in inter-helical interactions, as suggested by the 
decrease of 222/208 ellipticity ratio, more significant for F360L. These 
results, taken together, suggest a possible increase in the flexibility of the 
variants with respect to the wild type, as confirmed by molecular dynamics 
simulations. The importance of inter-helical interactions and the correct 
reciprocal positioning of H3 and H12 has been previously reported as a 
crucial point for PPARγ function (Kallenberger et al, 2003). 
The transcription activity of F360L, R357A, P467L, and Q286P 
PPAR γ variants was evaluated in comparison with wild-type PPAR γ LBD 
in the presence of the full agonist rosiglitazone and LT175, a partial agonist 
that binds to a different region of PPARγ. For this purpose, GAL4–PPAR 
chimeric receptors were expressed in transiently transfected HepG2 cells 
(Pinelli et al, 2005). As previously reported, the efficacy of both ligands 
remained basically unchanged towards F360L compared to the wild type, 
while the potency was significantly reduced (Lori et al, 2013). A remarkable 
lowering in both efficacy and potency was shown for R357A and P467L 
(Figure 1 and Table 1). Singular behavior has been observed for the mutant 
Q286P, which was completely inactive and insensitive to both rosiglitazone 
and LT175 (Figure 2). 
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Figure 1 - Transcription activity of wild type PPARγ and mutants in a PPARγ Gal4-
based assay. 
 
 
Table 1 - Transcription activity of PPARγ wild type and mutants in a PPARγ Gal4-
based assay 
  
48 
 
Figure 2 - Transcription activity. Transcription activity of rosiglitazone (A); and LT175 
(B) towards wild type PPARγ, PPARγ P467L, and PPARγ Q286P in a PPARγ Gal4-
based assay. 
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In this project we investigated the effects of PPARγ wild-type and the 
variants E324K and R397C in eukaryotic cell line, in order to see if 
adipogenesis pathway and some cancer related markers are differently 
expressed. The variants E324K and R397C are involved in one of the two salt 
bridges that may contribute to PPARγ stabilization and showed the most 
significant differences in term of stability and structural differences in 
solution and in dynamics. Interestingly, these two variants could not be 
expressed in the soluble fraction in E. coli even when different induction 
conditions were used. The experiments in eukaryotic cell line have been 
conducted in 3T3-L1 mouse embryonic fibroblast widely used for 
metabolism and obesity research (Wang et al, 2013). This cell line can 
differentiate into adipocites1 upon chemical induction. Human PPARγ C-HA 
tagged natural ORF mammalian expression plasmid and pCMV3 C-HA 
tagged empty plasmid were used to transfect low-passage 3T3-L1 
preadipocytes (kindly provided by Dr. F. Fazi, Sapienza University, Rome). 
The 3T3-L1 semiconfluent cell cultures have been transfected with the 
mammalian transient expression vectors harboring wild-type, E324K and 
R397C PPARγ, respectively, and the pCMV-C-HA empty vector. The 
morphological differentiation was assessed under light microscopy. The 
differential expression of adipogenesis markers in transfected cells and 
relative controls have been detected by western blot analysis. 
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Bromodomains 
In this study we selected three of the four BET proteins BRD2, BRD3 
and BRD4, that belong to the subfamily II of BRDs. Wild type and variants 
of BRD2(1), BRD4(1), BRD2(2), BRD3(2) and BRD4(2) have been studied 
in order to investigate the effect of amino acid substitutions on their structure 
in solution and on their thermal and thermodynamic stability. Several 
mutations in BET (bromo and extra terminal) BRDs (BRD2, BRD3 and 
BRD4) have been identified in humans and they may play an important role 
in several diseases. BRDs are the only known protein recognition module that 
selectively targets ε-N-acetylation of lysines. Many of these BRDs mutations 
have been related to cancer. The single amino acid substitutions significantly 
affect the tertiary and secondary structures of most of the BRDs variants 
studied, as indicated by the differences in their near and far UV CD spectra, 
when compared to the corresponding wild type proteins. The thermal and 
thermodynamic stability in particular of the BRD2(1) variants Y153H, 
E140K, R100L, D160N, D160Y and D161Y are remarkably lower than the 
corresponding wild type. The mutations induced by nsSNPs and found in 
cancer may cause alteration of native tertiary contacts and changes in thermal 
and/or thermodynamic stability. The interaction with inhibitors JQ1 and PFI-
1 was investigated by isothermal titration calorimetry experiments (ITC). The 
fitting of the binding isotherms with a one-site binding model gave the values 
of the Kd. The BRD2(1) variants, Y153H, D161Y and D161N and BRD3(2) 
H395R mutant show important differences in the Kd values, compared to 
wild-type. 
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Conclusion 
In conclusion, the variants of the PPARγ show significant differences 
in terms of tertiary and secondary structures as suggested by near and far UV 
CD spectra. The nsSNP PPARγ variants associated to metabolic disorders 
and cancer show alteration of dynamics that impair the correct reciprocal 
positioning of structural elements crucially important for PPARγ functioning. 
The mutations tend to destabilize the PPARγ LBD and increase the flexibility 
of the variants suggesting a possible involvement in a different network of 
protein interactions. These alterations may lead to change in the interactions 
with ligands and influence the multiple biological functions of this nuclear 
receptor. 
The single amino acid substitutions significantly affect the tertiary 
and secondary structures of most of the BRDs variants studied, as indicated 
by the differences in their near and far UV CD spectra, when compared to the 
corresponding wild type proteins. The significant alteration of the tertiary 
contacts observed in solution and the notable decrease in protein stability 
suggested an increase in conformational flexibility. All the mutated residues 
were solvent exposed, therefore they are not supposed to alter the global 
folding; however, a mutation of a residue on the surface may result in new 
and unknown interactions, thus the variants may acquire a new pattern of 
interactions and establish a novel and alternative network of protein-protein 
interconnection. This may be particularly important in BRDs that are 
physiologically embedded in multidomain proteins and multi-subunit 
complexes.  
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All in one, the results reported in this study point to alterations of 
tertiary contacts and change in protein flexibility and/or in stability for all the 
PPAR and BRDS natural variants found in pathological tissues. 
A detailed understanding of the changes of the investigated gene 
products at the molecular level to assess how genetic variations impact the 
protein folding, structure, function and interactions is required to develop 
new therapeutic strategies, particularly in the search of small molecules able 
to selectively interact with the variants, which is an essential preliminary step 
to personalized medicine, and help to identify new potential therapeutic 
targets. Precision medicine aims at classifying individuals into 
subpopulations that differ in their susceptibility to a particular disease. In 
addition, this approach may help in understanding the biology of the disease, 
in formulating the right diagnosis and prognosis and, at the last, it may 
provide information about the response to a specific pharmacological 
treatment. In conclusion, the structural analysis of  protein variants expressed 
in pathological tissues may help in understanding the disease at the molecular 
level and, since individuals carrying variants may respond differently to 
drugs, it may provide information for personalized drugs tailored to the 
individual variant. 
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